Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Non-Lethal Bone Marrow Necrosis under First-Line Arsenic Trioxide Therapy in Acute Promyelocytic Leukaemia

Non-Lethal Bone Marrow Necrosis under First-Line Arsenic Trioxide Therapy in Acute Promyelocytic... IntroductionAcute promyelocytic leukaemia (APL) is a special sub-group of acute myelocytic leukaemia characterised by proliferation of hypergranular promyelocytes and blasts with stalks of Auer rods (faggot cells). Karyotype analysis typically found t(15;17)(q22;q21) reciprocal fusion of 2 genes: PML located on the long arm of chromosome 15 and RARA (retinoid acid receptor) located on the long arm of chromosome 17. This fusion results in the formation of the PML/RARA gene, which is of pathogenetic significance.Arsenic trioxide (AT) can induce remission of relapsing or refractory APL. Some of the adverse effects of this drug include hepatic failure, life-threatening arrhythmia (torsades de pointes and ventricular fibrillation) and possibly sudden death [1]. In addition, bone marrow necrosis (BMN) is sometimes observed during autopsy. The pathophysiology of BMN has not been elucidated, but studies have shown that repeated administration and accumulation of AT (associated or not with chemotherapy) is principally responsible [1,2]. Here, we report the only case of non-lethal BMN that occurred upon initial exposure of a patient to AT.A 53-year-old man was admitted for chronic haemorrhage. The patient was pancytopenic, with more than 30% blasts with Auer rods present in the blood and bone marrow (BM). Biological exams revealed disseminated intra-vascular coagulation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Haematologica Karger

Non-Lethal Bone Marrow Necrosis under First-Line Arsenic Trioxide Therapy in Acute Promyelocytic Leukaemia

Download PDF
2 pages

Loading next page...
 
/lp/karger/non-lethal-bone-marrow-necrosis-under-first-line-arsenic-trioxide-McUgW3ytVj

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 2010 S. Karger AG, Basel
ISSN
0001-5792
eISSN
1421-9662
DOI
10.1159/000281063
Publisher site
See Article on Publisher Site

Abstract

IntroductionAcute promyelocytic leukaemia (APL) is a special sub-group of acute myelocytic leukaemia characterised by proliferation of hypergranular promyelocytes and blasts with stalks of Auer rods (faggot cells). Karyotype analysis typically found t(15;17)(q22;q21) reciprocal fusion of 2 genes: PML located on the long arm of chromosome 15 and RARA (retinoid acid receptor) located on the long arm of chromosome 17. This fusion results in the formation of the PML/RARA gene, which is of pathogenetic significance.Arsenic trioxide (AT) can induce remission of relapsing or refractory APL. Some of the adverse effects of this drug include hepatic failure, life-threatening arrhythmia (torsades de pointes and ventricular fibrillation) and possibly sudden death [1]. In addition, bone marrow necrosis (BMN) is sometimes observed during autopsy. The pathophysiology of BMN has not been elucidated, but studies have shown that repeated administration and accumulation of AT (associated or not with chemotherapy) is principally responsible [1,2]. Here, we report the only case of non-lethal BMN that occurred upon initial exposure of a patient to AT.A 53-year-old man was admitted for chronic haemorrhage. The patient was pancytopenic, with more than 30% blasts with Auer rods present in the blood and bone marrow (BM). Biological exams revealed disseminated intra-vascular coagulation.

Journal

Acta Haematologica – Karger

Published: Jan 1, 2010

There are no references for this article.